Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Https://www.illumina.com/content/dam/illumina-marketing/documents/products/other/ngs-pathology-primer-776-2017-024.pdf
The very first sentence on page 5 of the attached link demonstrates that Illumina do indeed consider that the analysis of CTCs using NGS to be an important part of their research work.
This morning's RNS stated the following:
''The Company is in discussions with other shareholders who have expressed interest in investing alongside the Chairman and largest shareholder on the same terms, notably, via a small placement of new ordinary shares at £0.15 per new ordinary share. An update will be provided shortly.''
How can the company offer new shares to certain other shareholders at the price of 15p when the company is negotiating with two bidders. This can't be allowed when the Senior staff have inside info. Please discuss...
Dear Seingred
Regarding your query on my SYnairgen shareholding. It is a sad story. I was still holding on to my very large Synairgen shareholding when the poor trial results were announced. I can't believe the risk I took. I lost a a very large sum of money. Well done to you for selling.
Fortunately with Condor at least I only have 18000 shares.
Is anyone trying to buy in this open offer through IG Index?
I've rang them twice now Monday afternoon and yesterday afternoon. They haven't set up the corporate action. Yesterday afternoon I was waiting on the phone for half an hour while they said they were going to set it up on my account while I was waiting. It still hasn't been done.
So they' ve just raised $1bn by issuing shares at $9.95 (£8.30). Yet on 27 May they bought 177,000 of their own shares at an average price of £9.39. Is this not a clear enough warning to those investors that still own shares in Carnival.
The share price gap is why I bought another 39000 at 8am today. Don't hold you hopes up for Kosovo mining results. There are plenty of junior miners with lots of gold and they are worth much less than the money they've put in to discovery the gold. Eg Condor Gold and Pure Gold.
LKABs problem with the Land & Environment Court relating to Kiruna increases the attractiveness of the Kallak site to LKAB. LKAB paid a £1bn dividend to the state this year from its profits on the 27 million tonnes of iron ore sold . Based on a pro rata rate of production (10m tonnes/yr) Kallak would yield a £330 million dividend to the state every year for 30 years. So for the swedish state to gain access to this future income it is easy to imagine that they'll pay £1bn for the asset.
Eric
I expect an offer anytime but it might not be until Beowulf have the Environmental Permit and the application for this EP is not being submitted until Q4 2023. The LKAB financial report posted earlier today by me was published many weeks ago, so it is nothing to do with todays 9% rise in Sweden.
https://mb.cision.com/Main/11419/3506121/1534697.pdf
This shows the phenomenal profit potential of Kallak.
https://verupharma.com/news/verus-novel-covid-19-drug-candidate-reduces-deaths-by-55-in-hospitalized-patients-in-interim-analysis-of-phase-3-study-independent-data-monitoring-committee-halts-study-early-for-overwhelmin/
I don't think this has been reported here before. In the 2 trading days following this announcement by Veru Pharma of a 55% reduction in death in a 150 person phase 3 trial the market cap of Veru Pharma rose from £295 to £1bn and remains at this elevated level 3 months later. This market reaction bodes well for Synairgen given the 70% reduction in progression to severe disease and death in the specially vulnerable cohort (circa 200 patients) of the SNG001 Phase 3 trial (623 patients).